How to determine CRISPR gene editing success in 2 weeks

Imagine CRISPR – but more efficient, reliable and flexible. SNIPER works in synergy with the CRISPR-Cas9 system to fulfill even the most challenging gene editing projects – including biallelic modifications, single base-pair changes and large DNA insertions. Read on to discover four examples of CRISPR-SNIPER in action.

Continue reading 

Pluripotent Potential for Clinical Application

Since their development in the mid-2000s, the versatile nature of induced Pluripotent Stem Cells (iPSCs) has unlocked the potential of curative approaches instead of symptom-reactive treatments. In particular, fields which deal with genetic disorders and regenerative therapies would benefit from this. The advancement of iPSC technology compliments the advent of personalized medicine, allowing for a future where individuals could be treated using autologous iPSCs.

Continue reading 

Stem Cells for Autism

In this post, we highlight recent advancements in stem cells as treatment and study of autism to commemorate World Autism Awareness Day (2 April 2019).

Autism spectrum disorder (ASD) is a complex developmental disability that impairs the ability to communicate and relate to others. Affecting 1% of the world population, it is the most commonly diagnosed childhood developmental disorder. In 2018, Centers for Disease Control (CDC) reported that rates of autism had increased to an estimated 1 in 59 children, up from 1 in 88 just six years ago.

Continue reading 

Spotlight: StemRNA Neuro iPSCs – Human Brain Neurons for Functional Assays

Human induced pluripotent stem cell (iPSCs) derived  neural models to study brain disease provide an unlimited resource for disease modelling as well as being a tool for drug screening for effective therapies. The limited access to viable patient neurons from brain tissue itself generates the need for functional and reproducible human neuron cell models. Such cells are now increasingly used for drug development studies as well as supporting research into mechanisms and pathways of various neurological diseases.

Continue reading 

Using human iPSCs as an in vitro model for regenerative medicine, drug screening and disease modelling

In translational medicine, research using primary patient samples is advantageous over cell lines as the expression of the protein under investigation is regulated by native elements in primary samples.

Continue reading 

Tissue Sourcing for the Development of iPSC-derived Disease Models

Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by drug treatment[3]. Such iPSC-based models enable studies to be performed under defined experimental conditions and in a reproducible manner.

Continue reading 

Press Release: ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

Funding will be used to improve efficiency of induced pluripotent stem cell production

Continue reading